|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
310,240,000 |
Market
Cap: |
6.83(B) |
Last
Volume: |
1,350,945 |
Avg
Vol: |
2,431,686 |
52
Week Range: |
$18.78 - $24.13 |
|
Level
I Sector: |
Industrials |
Level
II Sector: |
Diversified Services |
Level
III Sector: |
Research Services |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : 17.5 |
Insider 6 Months : 18.9 |
Insider 3/6 Months : 36.8 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
425,000 |
615,000 |
735,409 |
735,409 |
Total Buy Value |
$8,733,955 |
$12,666,689 |
$15,268,727 |
$15,268,727 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
3 |
4 |
4 |
Total Shares Sold |
88,818 |
210,838 |
601,659 |
1,021,249 |
Total Sell Value |
$1,938,121 |
$4,689,450 |
$12,908,109 |
$20,266,173 |
Total People Sold |
5 |
7 |
9 |
12 |
Total Sell Transactions |
6 |
9 |
17 |
28 |
End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cohen Charles |
Director |
|
2021-02-24 |
4 |
S |
$22.69 |
$907,600 |
D/D |
(40,000) |
181,375 |
|
19% |
|
Cohen Charles |
Director |
|
2021-02-24 |
4 |
OE |
$3.38 |
$135,200 |
D/D |
40,000 |
221,375 |
|
- |
|
Willsey Lance |
Director |
|
2021-02-23 |
4 |
S |
$21.92 |
$877,136 |
D/D |
(40,000) |
424,415 |
|
18% |
|
Willsey Lance |
Director |
|
2021-02-23 |
4 |
OE |
$3.38 |
$135,200 |
D/D |
40,000 |
464,415 |
|
- |
|
Poste George |
Director |
|
2021-02-22 |
4 |
OE |
$3.38 |
$135,200 |
D/D |
40,000 |
197,992 |
|
- |
|
Marchesi Vincent T |
Director |
|
2021-02-22 |
4 |
S |
$22.29 |
$537,122 |
D/D |
(24,097) |
66,115 |
|
15% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2021-02-18 |
4 |
S |
$22.35 |
$1,117,500 |
D/D |
(50,000) |
540,597 |
|
19% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2021-02-18 |
4 |
OE |
$1.70 |
$85,000 |
D/D |
50,000 |
590,597 |
|
- |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2021-02-17 |
4 |
S |
$22.50 |
$1,125,000 |
D/D |
(50,000) |
540,597 |
|
21% |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2021-02-17 |
4 |
OE |
$1.70 |
$85,000 |
D/D |
50,000 |
590,597 |
|
- |
|
Willsey Lance |
Director |
|
2021-02-16 |
4 |
S |
$21.90 |
$1,095,000 |
D/D |
(50,000) |
424,415 |
|
-7% |
|
Feldbaum Carl B |
Director |
|
2021-02-16 |
4 |
S |
$21.96 |
$439,200 |
D/D |
(20,000) |
8,521 |
|
-7% |
|
Feldbaum Carl B |
Director |
|
2021-02-16 |
4 |
OE |
$3.38 |
$67,600 |
D/D |
20,000 |
28,521 |
|
- |
|
Lamb Peter |
EVP, Scientific Strategy & CSO |
|
2021-02-15 |
4 |
D |
$21.91 |
$81,461 |
D/D |
(3,718) |
340,072 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2021-02-15 |
4 |
D |
$21.91 |
$214,477 |
D/D |
(9,789) |
559,187 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-02-15 |
4 |
D |
$21.91 |
$30,674 |
D/D |
(1,400) |
245,487 |
|
- |
|
Schwab Gisela Md |
Pres, Prod Dev & Med Aff & CMO |
|
2021-02-15 |
4 |
D |
$21.91 |
$62,619 |
D/D |
(2,858) |
540,597 |
|
- |
|
Hessekiel Jeffrey |
EVP and General Counsel |
|
2021-02-15 |
4 |
D |
$21.91 |
$36,918 |
D/D |
(1,685) |
589,113 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-02-15 |
4 |
D |
$21.91 |
$89,941 |
D/D |
(4,105) |
292,441 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-02-12 |
4 |
S |
$21.57 |
$970,650 |
D/D |
(45,000) |
246,887 |
|
-4% |
|
Morrissey Michael M |
President and CEO |
|
2021-02-03 |
4 |
D |
$22.56 |
$1,470,686 |
D/D |
(65,190) |
568,976 |
|
- |
|
Morrissey Michael M |
President and CEO |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
23,238 |
409,879 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-02-03 |
4 |
D |
$22.56 |
$254,184 |
D/D |
(11,267) |
291,887 |
|
- |
|
Haley Patrick J. |
EVP, Commercial |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
63,909 |
303,154 |
|
- |
|
Senner Christopher J. |
EVP and CFO |
|
2021-02-03 |
4 |
D |
$22.56 |
$410,727 |
D/D |
(18,206) |
296,546 |
|
- |
|
1438 Records found
|
|
Page 13 of 58 |
|
|